The DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives.
Open accessAbstract
Hallucinogen Persisting Perception Disorder (HPPD) is a rare, and therefore, poorly understood condition linked to hallucinogenic drugs consumption. The prevalence of this disorder is low; the condition is more often diagnosed in individuals with a history of previous psychological issues or substance misuse, but it can arise in anyone, even after a single exposure to triggering drugs. The aims of the present study are to review all the original studies about HPPD in order to evaluate the following: (1) the possible suggested etiologies; (2) the possible hallucinogens involved in HPPD induction; (3) the clinical features of both HPPD I and II; (4) the possible psychiatric comorbidities; and (5) the available and potential therapeutic strategies. We searched PubMed to identify original studies about psychedelics and Hallucinogen Persisting Perception Disorder (HPPD). Our research yielded a total of 45 papers, which have been analyzed and tabled to provide readers with the most updated and comprehensive literature review about the clinical features and treatment options for HPPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Arguably, the most notorious cause of HPPD is lysergic acid diethylamide (LSD), although the condition can also arise from substances such as mescaline, psilocybin, ibogaine, ayahuasca, ketamine, 3,4-methylenedioxymethamphetamine (MDMA or ecstasy), cannabis, and even alcohol.3–5”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An earlier review by Martinotti and colleagues3 was also based on 16 articles. The authors mentioned efficacy for an even wider range of pharmacological agents and recommended combining several different medications to treat HPPD and any underlying or new comorbid disorders.”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pharmacological interventions are all experimental and practice-based.”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Case reports and small-scale pharmacological studies show promising results with antipsychotics, antidepressants, antiepileptics, and benzodiazepines.”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“The efficacy of these medications, however, remains unclear.3–5”
From Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review (2025) · cites this paper as [3]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Thalamic Relay Functions and Their Role in Corticocortical Communication
Guillery, R. W., & Sherman, S. M. (2002) · Neuron · doi:10.1016/s0896-6273(01)00582-7 · Cited by 636
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Amanita muscaria: chemistry, biology, toxicology, and ethnomycology
Michelot, D., & Melendez-Howell, L. M. (2003) · Mycological Research · doi:10.1017/s0953756203007305 · Cited by 260
Cinosi, E., Martinotti, G., Simonato, P., Singh, D., Demetrovics, Z., Roman-Urrestarazu, A., Bersani, F. S., Vicknasingam, B., Piazzon, G., Li, J.-H., et al. (2015) · BioMed Research International · doi:10.1155/2015/968786 · Cited by 234
Self-citationCaton, C. L. M., Drake, R. E., Hasin, D. S., Dominguez, B., Shrout, P. E., Samet, S., & Schanzer, W. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.137 · Cited by 231
Hallucinogen persisting perception disorder: what do we know after 50 years?
Halpern, J. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00306-x · Cited by 219
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201 · cited 2×
“The effectiveness of Benzodiazepines may be related to their activity on the cortical serotonergic-inhibitory inter-neurons with GABAergic outputs [2,4].”
BackgroundThe Psychopharmacology of Hallucinogens
Abraham, H., Aldridge, A. M., & Gogia, P. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00136-2 · Cited by 172
The Relation Between Migraine, Typical Migraine Aura and “Visual Snow”
Schankin, C. J., Maniyar, F. H., Sprenger, T., Chou, D. E., Eller, M., & Goadsby, P. J. (2014) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12378 · Cited by 171
Research works printed but not linked: 10
- Hofmann, A. (1980). LSD: My Problem Child, McGraw-Hill.
- Lerner, 2002, LSD-induced hallucinogen persisting perception disorder with depressive features treatment with reboxetine, Isr. J. Psychiatry Relat. Sci., 39, 100
- Lerner, A.G. (2017, January 23–26). Flashbacks and Hppd (Hallucinogenic Persisting Perception Disorder): Clinical Aspects and Pharmacological Treatment. Proceedings of the First World Congress of the World Association on Dual Disorders, Madrid, Spain.
- Lerner, 2011, Benign and time-limited visual disturbances (Flashbacks) in recent abstinent high-potency heavy smokers, Isr. J. Psychiatry Relat. Sci., 48, 25
- Stahl, S.M. (1996). Stahl’s Essential Psychopharmacology, Cambridge University Press. [1st ed.].
- Goodman, 2014, Synthetic Cannabis Substances (SPS) Use and Hallucinogen Persisting Perception Disorder (HPPD): Two case reports, Isr. J. Psychiatry Relat. Sci., 51, 277
- van der Kolk, B.A. (1984). Propanolol and Clonidine in the Treatment of Post Traumatic Disorders of War, American Psychiatric Press. Post Traumatic Stress Disorder: Psychological and Biological Sequelae.
- Noushad, 2015, 25 years of Hallucinogen Persisting Perception Disorder—A diagnostic challenge, Br. J. Med. Pract., 8, a805
- Aicardi, J. (2008). Epilepsy: A Comprehensive Textbook, Wolters Kluwer Health/Lippincott Williams & Wilkins. [2nd ed.].
- Martinotti, 2015, The exogenous model of induced psychotic experience in addiction, Res. Adv. Psychiatry, 2, 81
Cited by
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5106-2 · Cited by 174
Case analysis of long-term negative psychological responses to psychedelics
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41145-x · Cited by 135
Visual snow syndrome: A clinical and phenotypical description of 1,100 cases
Puledda, F., Schankin, C. J., & Goadsby, P. J. (2020) · Neurology · doi:10.1212/wnl.0000000000008909 · Cited by 124
Metadata
- Authors
- Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A.
- Affiliations
- University of Hertfordshire (GB)
- Università Cattolica del Sacro Cuore (IT)
- University of Chieti-Pescara (IT)
- Department of Neuroscience, Imaging and Clinical Sciences, University “G. d’Annunzio”, 66100 Chieti, Italy
- Tel Aviv University (IL)
- Corresponding author
- Santacroce, Rita
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2018-03-16
- Volume
- 8
- Issue
- 3
- Pages
- 47
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC5870365
- OpenAlex
- W2790481213
- Cited by
- 171
- References
- 84
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 24 · 2023: 22 · 2022: 24 · 2021: 26 · 2020: 33 · 2019: 8 · 2018: 6
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- hallucinogen persisting perception disorder, HPPD, hallucinogens, psychedelics, etiology, clinical features, psychiatric comorbidity, substance abuse, treatment options
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. https://app.cochat.ai/papers/10.3390/brainsci8030047
- The paper
- Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A. (2018). Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sciences. https://doi.org/10.3390/brainsci8030047
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
